Spectrum Pharmaceuticals, Inc. (SPPI) Cut to Sell at Zacks Investment Research

Spectrum Pharmaceuticals, Inc. (SPPI) Cut to Sell at Zacks Investment Research


According to Zacks, "Shares of Spectrum have underperformed the Medical Drugs industry in the past one year. The company's efforts to gain approval for Qapzola in the U.S. suffered a setback with the FDA issuing a Complete Response Letter in Nov 2016.



from Biotech News